Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer

21 Apr 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35462012
DOI: 10.1016/j.phrs.2022.106232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancerPMID 35462012Read ↗

The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testingSemantic proximity Read ↗

Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug ResponsesSemantic proximity Read ↗

Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testingSemantic proximity Read ↗

Organoid Models Established from Primary Tumors and Patient-Derived Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer PatientsSemantic proximity Read ↗

Patient-Derived Organoids Functionally Stratify Epithelial Ovarian Cancer into Clinically Relevant Chemotherapy Response PhenotypesSemantic proximity Read ↗

Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid modelsSemantic proximity Read ↗

Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responsesSemantic proximity Read ↗

Ascites-Derived Organoids for Prediction of Treatment Response and Clinical Management in Ovarian Cancer: A Case ReportSemantic proximity Read ↗

Longitudinal Prediction of Drug Response in High-Grade Serous Ovarian Cancer Organoid Cultures Aligning with Clinical ResponsesSemantic proximity Read ↗

In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity Read ↗

Development of patient derived organoids for cancer drug screening applicationsSemantic proximity Read ↗

Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screeningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.